• Korean Journal of Poultry Science
• /
• v.32 no.2
• /
• pp.113-123
• /
• 2005

Avian influenza (AI) virus (AIV) is distributed worldwide and it has been isolated from various species of wild and domestic birds. AI transfers with high speed and shows diverse pathogenicity syndroms. In Korea, several low Pathogenic AIV, H9N2, have been isolated from the commercial farms with severe decrease of egg production and mortality resulted in severe economic loss since 1996. Therefore, it has been requested to develop AI vaccines to prevent clinical signs and economic losses from the field infection of AIV. To develop a killed vaccine that efficiently prevents low pathogenic AIV (H9N2), evaluation on the pathogenicity and selection of an inactivator for H9N2 is taking place and is being tested safety and immunogenicity of vaccine produced. Based on the pathogenicity test and viral reisolation test, the ADL0401 isolate is the characteristic low pathogenic AIVs and has fairly similar biologic functions compared with MS96 which is the official low pathogenic AIV (H9N2) and one of the predominant AIV isolated from poultry farms in Korea. In antigenicity tests, the ADL0401 and MS96 virus have no significant antigenic difference. In inactivation tests, the ADL0401 isolates can be easily inactivated with $0.1\%$ Formalin at $37^{\circ}C$ within 1 hour with a little decrease of HA titer. The vaccine developed in the present report has no harmful effect on bird and forms good immune capability. Therefore, the isolates, ADL0401 can be used for a killed vaccine which can reduce the clinical signs and viral shedding in the birds infected with H9N2 low pathogenic AIVs.

• Journal of the korean veterinary medical association
• /
• v.45 no.8
• /
• pp.746-757
• /
• 2009

국립수의과학검역원과의 공동연구과제(소 아까바네병, 츄잔병, 아이노 바이러스혼합불활화 예방약 산업화)에 의해 실시한 시험을 통하여 소 아까바네병, 츄잔병, 아이노 바이러스병에 대한 예방약인(소 츄잔병, 아까바네병, 아이노병 불활화 혼합오일백신) 면역원성 시험 및 야외에서의 적용시험 등을 실시한 결과를 요약하면 다음과 같다. 1. 혼합오일백신의 기니픽에 대한 면역원성 시험에서 아까바네 바이러스, 아이노 바이러스 및 츄잔 바이러스에 대한 중화항체가는 시험백신을 3주 간격 2회 접종한 시험구가 무접종 대조구에 비하여 높게 나타났다. 2. 혼합오일백신의 야외농장 3곳의 육성우에 대한 면역원성 시험에서 시험백신을 2회 접종 후 아까바네 바이러스의 항체가는 평균 102배, 115배 및 134배이였으며, 아이노 바이러스의 항체가는 평균 8배, 24배 및 27배로 나타났고, 츄잔 바이러스의 경우에는 3곳의 농장에서 평균 30배, 46배 및 172배로 나타났다. 3. 야외농장 2곳에서 혼합오일백신을 임신우에 2회 접종하였을 때, 중화항체가는 아까바네 바이러스가 평균 64배와 93배를 나타내었고, 아이노 바이러스의 중화항체가는 평균 70배와 96배, 츄잔 바이러스의 중화항체가는 평균 20배와 20배로 나타났다. 4. 혼합오일백신은 임신우에 대한 공격접종시험에서 시험백신을 3주 간격으로 2회 접종 후 3주째의 중화항체가는 아까바네 바이러스가 128$\sim$256배이었고, 아이노 바이러스는 64$\sim$256배로 나타났고, 츄잔 바이러스는 8$\sim$32배이었다. 공격 접종 후 부검 전의 중화항체가는 아까바네 바이러스가 16$\sim$128배로 나타났고, 아이노 바이러스는 32$\sim$128배였으며, 츄잔 바이러스는 4$\sim$16배였다. 혼합오일백신을 임신우에 3주 간격 2회 접종한 뒤 공격접종하여 채혈한 혈청의 면역원성이 무접종 대조군에 비하여 방어효과가 우수하였다. 5. 3롯트의 시험백신을 선정하여 2$\sim$7$^{\circ}C$의 냉암소에 보존하면서 보존 기간별(제조당시, 6개월, 12개월, 15개월, 18개월)로 특성시험, 무균시험 및 안전시험을 실시한 결과, 전 보존기간에 마우스 및 기니픽에 대한 안전성이 인정되었으며, 보존기간별로 시험백신의 기니픽에 대한 면역원성 시험을 실시한 결과, 기니픽의 중화항체가는 15개월까지 지속되는 것으로 나타났다.

• Pediatric Infection and Vaccine
• /
• v.8 no.2
• /
• pp.160-167
• /
• 2001

Purpose : To assess the immunogenicity, safety, and tolerability of hepatitis A vaccine ($VAQTA^{TM}$) in healthy children and adolescents. Methods : Eligible subjects aged 2 to 17 years received 25 U/0.5 mL of $VAQTA^{TM}$ intramuscularly at 0 and 24 week schedule. Bleeds were obtained prior to vaccination and 4 weeks after the second dose to ascertain serostatus. To detect antibody to HAV after vaccination with an inactivated HA vaccine, a modification of the $Abbott^{(R)}$ HAVAB kit was used. Sample with titers ${\geq}10$ mIU/mL were considered seroconverted. Adverse experiences were monitored. Results : 102 subjects(54 male, 48 female) were enrolled. The mean age was $6.8{\pm}3.5$ years. Two subjects were seropositive, two were lost of follow up. 88 subjects were available for a per protocol analysis and 90 for all subjects with serology after the second dose, and ten withdral. All subjects(95% CI, 94.8~100) seroconverted. Geometric mean titers was 7,991.1(95% CI, 6,481.1~9,852.7) with very little difference in per protocol analysis and all subjects analysis. Adverse experiences to $VAQTA^{TM}$ were generally mild and transient. Conclusion : The pediatric two-dose regimen of $VAQTA^{TM}$ was found to be highly immunogenic, generally well tolerated and resulted in 100% seroconversion. Regarding Korea is in transition from a high to low risk region resulting in a paradox increase of clinical disease and disease burden, routine vaccination should be considered in order to control hepatitis A effectively.

• Pediatric Infection and Vaccine
• /
• v.7 no.1
• /
• pp.120-128
• /
• 2000

Purpose : Active immunization against hepatitis A with an inactivated vaccine reveals excellent immunogenicity, tolerability and protective efficacy. Inactivated hepatitis A vaccines have been selectively used since 1996 in Korea to prevent hepatitis A. This study was performed to assess the immunogenicity and reactogenicity after two doses of HM175 strain hepatitis A vaccine in healthy Korean children. Methods : 128 healthy children(M/F; 65/63) aged 1 to 15 years, who were seronegative for hepaitatis A, participated in this study. A alum-adsorbed vaccine containing 720 EL.U of antigen form HM175 hepatitis A strain per 0.5 mL dose was injected intramuscularly on the deltoid area. The second dose was given 6 months later, Anti-HAV antibodies were measured by ELISA before and 1 month after each vaccination to assess the immunogenicity. Any local and general adverse events were reported by patients parents with the prepared questionnaire after each vaccination. Results : 120 volunteers(M/F; 60/60) completed the whole series of the study. Seroconversion occurred in all cases after primary and booster vaccination. The mean anti-HAV antibody titer after primary vaccination was 389.2mIU/mL, and 3,609mIU/mL after booster vaccination. And levels of anti-HAV antibodies after booster immunization were significantly higher in female children. The most common local adverse event was soreness on the injection site, but it was mild and resolves within 3 days. Fever was not reported after booster vaccination. Conclusion : Based on these data, we conclude that the inactivated HM175 strain hepatitis A vaccine is highly immunogenic and tolerable in healthy Korean children.

• Proceedings of the Korean Society of Veterinary Service Conference
• /
• 1999.05a
• /
• pp.181.2-182
• /
• 1999

• Journal of Veterinary Clinics
• /
• v.16 no.2
• /
• pp.328-331
• /
• 1999

Theileriosis에 대한 효율적인 예방대책을 마련하기 위한 일환으로 발현된 T. sergenti 재조합 항원단백질의 면역원성을 조사하였다. 먼저, E. coli 단백질 발현 vector인 pQE 32 plasmid vector를 이용하여 발현된 T. sergenti의 재조합 막표면단백질(KTs-MP)을 4개월령의 유우 송아지에 접종하였다. 그리고 접종된 송아지의 혈액변화상과 T. sergenti에 대한 항체가의 변화상을 분석한 결과, 재조합단백질의 접종에 의하여 항체가가 상승되는 것을 알 수 있었다. 그러나 재조합단백질의 접종만으로는 T. sergenti의 감염을 완전하게 예방하지는 못하였다.

• Proceedings of the Korean Nutrition Society Conference
• /
• 2003.05a
• /
• pp.204.2-204.2
• /
• 2003

• Korean Journal of Microbiology
• /
• v.38 no.1
• /
• pp.38-44
• /
• 2002

Pneumococcal surfacce protein A (PspA) is an important virulence factor and an antigenically variable surface protein of the pneumococci. To purify the PspA from S. pneumoniae KNIH1156 , a clinical isolate (type 19F), we have taken advantage of the fact that PspA is released from the surface of pneumococci into the medium by growing in a CDM-ET medium and PspA is capable of binding human lactoferrin, the iron carrier protein. PspA of S. pneumoniae KNIH1156 was purified from culture supernatant by human lactoferrin (hLf) affinity chromatography. The purified PspA was confirmed with anti-PspA antiserum and also had the binding capacity to hLf specifically. To determine whether the purified PspA could elicit protection in mice against pneumococcal inflection, we immunized the mice with purified PspA and subsequently challenged with S. pneumoniae KNIH1156. Immunization with purified PspA protected mice from 500 times the $LD^{50}$ of S. pneumoniae KNIH1156. Therefore, it has been shown that purified PspA fromS. pneumoniae KNIH1156 (type 19F) is a protective immunogen.

• Clinical and Experimental Pediatrics
• /
• v.50 no.4
• /
• pp.355-362
• /
• 2007

Purpose : We conducted the study to evaluate the immunogenicity and safety of three component DTaP vaccine ($Infanrix^{(R)}$) in a group of Korean healthy infants on a three-dose primary vaccination. And we compared the immunogenicity of this DTaP vaccine with two component DTaP vaccine which has been widely used in Korea. Methods : We enrolled one hundred fifty one healthy infants aged 8-9 weeks. These infants were vaccinated at age 2, 4 and 6 months of age with three component DTaP vaccine. Solicited adverse events were actively monitored for 72 hours following each vaccination, and all adverse events after each vaccination were observed for three weeks. Anti-diphtheria toxoid Ab., anti-tetanus toxoid Ab., anti-pertussis toxin Ab., anti-filamentous hemagglutinin Ab., and anti-pertactin Ab. were measured using ELISA for assessing immunogenicity of study vaccine in 60 infants. Immunogenicity analysis of two component DTaP vaccine was performed with same methods in 14 infants as control. Results : The seroconversion rates of anti-diphtheria toxoid Ab, anti-tetanus toxoid Ab. anti-filamentous hemagglutinin Ab. were 100% in both group. Seroconversion rate of anti-pertactin Ab in study group was 100%, but the rate in control group was 50%. However, geometric mean concentration of anti-pertussis toxin Ab. was higher in control group. Mild local and systemic reactions were observed within three days after vaccination, and no serious adverse events related study vaccine were happened during study period. Conclusion : Our study results suggest that three component DTaP vaccine ($Infanrix^{(R)}$) is a well-tolerable and high immunogenic vaccine, especially anti-Pertactin Ab. of the study vaccine is very immunogenic. It can be available as routine DTaP vaccination in our infants.

• Parasites, Hosts and Diseases
• /
• v.32 no.2
• /
• pp.111-116
• /
• 1994

Immunoblot analysis utilizing bovine sera from naturally or experimentally infected with Theileria sergenti were used to determine the immunodominant polypeptides of T sergenti (Korean isolated. The previously recognized major bands, 18 kDa,29 kDa, 34 kDa and 45 kDa, were excised after electrophoresis and transfer to PnF membrane. The individual bands were sequenced. The 34 kDa polypeptide which was the most antigenic and immunogenic peptide was observed in the Western blot. However, Chou-Fasman prediction sites (antigenic site) for antigen determinants of the 45 kDa, 34 kDa, 29 kDa and 18 kDa polypeptide were 6, 4, 2 and 0, respectively. However, the 45 kDa polypetide showed no reaction with anti- T sergenti hyperimmune serum.